PA Medical News about Osteitis Deformans

Your Unread Messages

See All

Tracy Hampton, PhD

Clinical Trial Watch

Lapatinib Helps Subset of Patients with Hepatocellular Carcinoma

Roberta Buell, MBA
Congress Proposes SGR Fix

Dorothy J. Schirf, MD

Technology Advances

Nanotech Effort with Glioblastoma - Impressive or Impractical?

Sara Hartley

Cancer Science

Using Embryonic Stem Cells to Test Breast Cancer Genes

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Use of Antiemetic Agents in Acute Gastroenteritis

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Serum homocysteine, folate and vitamin B12 in patients with Paget's disease of bone: the effect of zoledronic acid
Journal of Bone and Mineral Metabolism, 11/06/09

Polyzos SA et al. – These data suggest that serum HCY levels are increased in patients with PDB. A single ZOL infusion results in a decrease in HCY levels that might represent another mechanism for the reduction of the activity of PDB achieved by ZOL.

Exclusive Author Commentary
Stergios A. Polyzos, 11/06/09

This is the first report of serum homocysteine (HCY), folate and vitamin B12 in patients with Paget's disease of bone (PDB). There are limited data regarding the effect of bisphosphonates on HCY, folate or vitamin B12. In this study, higher serum HCY and folate levels were observed in the pagetic compared with the control group and HCY levels were decreased 3 months after zoledronic acid (ZOL) infusion and remained essentially unchanged up to the end of the study. Since the increased HCY could lead to increased activation and formation of osteoclasts, this effect of ZOL on HCY might represent another mechanism for the reduction of the activity of PDB achieved by ZOL.